Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biogen Idec Canada has launched FAMPYRA (fampridine sustained release tablets or fampridine SR) for prescription for patients living with multiple sclerosis (MS) in Canada.
Subscribe to our email newsletter
FAMPYRA received Health Canada approval for the symptomatic improvement of walking in adult MS patients with walking disability.
The approval of FAMPYRA was based on the results of two Phase III clinical trials, which demonstrated efficacy in people with all types of MS.
A significantly greater proportion of patients taking FAMPYRA had consistent improvement in walking speed when compared to placebo, the studies reported.
MS is often debilitating disease of the central nervous system that attacks the protective covering, or myelin, of the brain and spinal cord, causing inflammation and damage.